Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 8/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Wortmannin SCHEMBL1147299 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL19737003 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL12650003 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL18022829 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL12162186 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL4531 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL14174545 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL14233191 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL13166020 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT | |
| Wortmannin SCHEMBL4530 | 1.00 | PIK3C3 (1.00) | PIK3C3PIK3CAPIK3R1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139009-A1 | PREFUSION-STABILIZED CMV GB PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12577544-B2 | Modified PH129 polymerase and uses thereof | Singular Genomics Systems, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250320474-A1 | MODIFIED ENZYMES AND USES THEREOF | SINGULAR GENOMICS SYSTEMS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250263502-A1 | Anti-CD98hc VNARs for Crossing the Blood Brain Barrier and Type IV VNAR Libraries | OSSIANIX, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12258414-B2 | Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries | OSSIANIX, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-12227774-B2 | Modified PHI29 DNA polymerases and uses thereof | Singular Genomics Systems, Inc. (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2025006262-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OMNIAB, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240294887-A1 | MODIFIED ENZYMES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2024-09-05 | — | — | US | disclosed |
| WO-2024076991-A2 | MODIFIED ENZYMES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2581081-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2572712-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20090324489-A1 | Wortmannin conjugates and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2009-12-31 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080312313-A1 | Inhibitors of Ccr9 Activity | CARBALLIDO HERRERA JOSE M | 2008-12-18 | — | — | US | disclosed |
| US-20080248097-A1 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| US-20080248097-A1 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-10-09 | — | — | US | disclosed |
| WO-2008106129-A2 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312313-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | PIK3C3 1769/4885PIK3CA 3629/4885PIK3R1 3532/4885 |
| US-12577544-B2 | Modified PH129 polymerase and uses thereof | POLR1E, POLM, POLQ | PIK3C3 1514/4885PIK3CA 1780/4885PIK3R1 2765/4885 |
| US-20080248097-A1 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY | MCL1, NUP205, ABCB1 | PIK3C3 4742/4885PIK3CA 1204/4885PIK3R1 1065/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | PIK3C3 3977/4885PIK3CA 2503/4885PIK3R1 2548/4885 |
| US-20090324489-A1 | Wortmannin conjugates and uses thereof | PIK3CG, PIK3C3, PIK3CA | PIK3C3 2/4885PIK3CA 3/4885PIK3R1 19/4885 |
| US-20260139009-A1 | PREFUSION-STABILIZED CMV GB PROTEINS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GHDC, IGF2BP3 | PIK3C3 4004/4885PIK3CA 4080/4885PIK3R1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.